Isoniazid/rifapentine

Isoniazid/rifapentine
Combination of
IsoniazidAntibiotic
RifapentineRifamycin
Names
Other namesIsoniazid regimen with rifapentine
Clinical data
Main usesTuberculosis[1]
Side effectsLiver problems, allergic reactions[2]
InteractionsMany[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Duration12 weeks[2]

Isoniazid/rifapentine is a combination medication used to treat tuberculosis.[1] Specifically it is used once a week for three months for latent TB.[3] It decreases risks of progress from infection to disease by 60 to 90%.[2] It is taken by mouth once per week for 12 weeks.[2]

Side effects may include liver problems, low platelets, and allergic reactions.[2][1] Use is not recommended in pregnancy.[1] There are many potential medication interactions.[1] It is a combination of isoniazid and rifapentine.[2] Isoniazid works in part by disrupting the formation of the bacteria's cell wall.[4] Rifapentine is in the rifamycin family of medication and works by blocking DNA-dependent RNA polymerase.[5]

The combination was added to the World Health Organization's List of Essential Medicines in 2021.[6] The individual medications were previously included in 2015 and 1977.[2] As of 2022 the individual medications costs about 73 USD per course of treatment in the developing world.[2]

Medical use

Dosage

Each pill contains 300 mg of isoniazid and 300 mg rifapentine.[6]

References

  1. 1 2 3 4 5 6 "Use of rifapentine and isoniazid combination therapy for the treatment of latent tuberculosis infection in Ontario" (PDF). Archived (PDF) from the original on 2 December 2022. Retrieved 1 December 2022.
  2. 1 2 3 4 5 6 7 8 "Rifapentine + isoniazid 2021 Expert Committee on Selection and Use of Essential Medicines Application review" (PDF). Archived (PDF) from the original on 2 December 2022. Retrieved 2 December 2022.
  3. ↑ "Latent TB Infection Medicine- Isoniazid & Rifapentine | TB | CDC". www.cdc.gov. 15 August 2022. Archived from the original on 27 June 2022. Retrieved 1 December 2022.
  4. ↑ "Isoniazid". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  5. ↑ "Rifapentine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  6. 1 2 World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.